Post 4 Prevention
Leadership 2017-05-24T23:07:22+00:00


The HeritX team is ready to lead the charge, with unique experience and proven success in developing break-through therapies, deep expertise in oncology and relationships spreading broadly across academia, industry and government. The HeritX leadership team has a personal stake in preventing inherited cancer, turning their professional careers exclusively to this mission.

thomas bock

Thomas A. Bock MD, MBA
Chairman and Chief Executive Officer


Prior to founding HeritX, Thomas was a practicing oncologist and academic researcher whose research spanned leading academic centers as well as the National Institutes of Health’s Human Genome Research Institute (stem cell and genetic therapies). Thomas also holds an MBA from Columbia University and has served in executive management positions in leading biopharmaceutical companies including Amgen, Novartis, Celgene and Alexion. His passion for cancer prevention stems from his family’s BRCA mutation. His wife, Irina, is a BRCA1 breast cancer and melanoma survivor whose father and uncle died of pancreatic cancer. Thomas serves on the Board of Advisors at Columbia Business School and Robertson Therapeutic Development Fund at Rockefeller University. He is also Past President of FORCE, a national hereditary breast and ovarian cancer advocacy organization, and a former officer of Rotary International in Mendham, NJ. Thomas and Irina have three children and live in Morris County, NJ.

Joi Morris, JD
Senior Vice President, Alliances and General Counsel

Joi joined Thomas in founding HeritX in 2015. She is a BRCA2 carrier and an experienced lawyer and patient advocate. She brings a wealth of legal and governance experience as well as a passion for including the voice of the patient community in research. She is also the author of Positive Results: Making the Best Decisions When You’re at High Risk for Breast or Ovarian Cancer, the first consumer guidebook on BRCA cancers, with Dr. Ora Karp Gordon. Joi serves as an Advocate in Science and grant reviewer for Susan G. Komen for the Cure and is Past Vice President of FORCE, a national hereditary breast and ovarian cancer advocacy organization. She and her husband Matt have two children and live in Santa Monica, CA.

doug hager

Douglas Hager, PhD
Senior Vice President of Project Management and Operations

Douglas is a Harvard graduate and was previously the Global Head of Project Management at Novartis, responsible for the largest oncology product portfolio across the biopharmaceutical industry. As one of the top biopharmaceutical executives in his field, he brings a unique leadership experience in global project management and drug development from the stage of basic research to FDA approval as well as biomedical licensing and alliances. He and his wife Mary have two children and live in Morris County, NJ.


Thomas A. Bock (Chairman) – Global R&D leader in oncology and orphan diseases and member of the executive management team of Alexion (rated #2 in innovation across all industries, Forbes 2014)

Joi Morris – Experienced attorney and author of the first guidebook on hereditary breast and ovarian cancer (Award winner 2011, American Medical Writers Association)

Jay Rasulo (Treasurer and independent trustee) – Fortune 100 leader and former Chief Financial Officer of The Walt Disney Company; Board Chairman of Los Angeles Philharmonic

Kirk Patrick (Secretary and independent trustee) – Recognized legal expert and former partner in Gibson, Dunn & Crutcher (one of the largest global law firms)

Jan Livingston-Mokhtari (independent trustee) – Global communications leader and Executive Vice President and Chief Creative Officer at FOX Networks Group (named Most Creative Woman in Advertising, 2013)

Howard Janzen (independent trustee) – Technology pioneer and Executive Chairman of Cool Planet Energy Systems (named Top 25 Disruptor, 2014). Member, Governor’s Science and Technology Council for the State of Oklahoma

Rolf Altorfer – Chief Executive Officer, Kuehne + Nagel (Ret.)

Rainer Boehm, MD – Chief Commercial Officer, Novartis Pharmaceuticals (Ret.)

Bill Burke – President, Mendham Capital Management

Tom Dubin – Chief Legal Officer, Alexion Pharmaceuticals (Ret.)

Thomas Hofstetter – Chief Executive Officer, Points Group

Eric Mayer – Philanthropist, humanitarian and Holocaust survivor